Novel Therapeutics and Antifungal Agents

Abstract

Fungal infections represent an escalating global health threat, with invasive mycoses contributing to high morbidity and mortality, particularly in immunocompromised populations. The therapeutic landscape is constrained by reliance on only a few antifungal classes, each limited by toxicity, fungistatic activity, or emerging drug resistance. In recent years, significant advances have been made in developing novel antifungal agents targeting innovative targets and mechanisms of action. Next-generation azoles, such as oteseconazole and VT-1598, offer improved specificity for fungal sterol 14α-demethylase (CYP51) while reducing host toxicity. New echinocandin derivatives, such as rezafungin, exhibit improved pharmacokinetics, enabling less frequent dosing. Previously unexploited pathways, currently under exploration, include glycosylphosphatidylinositol-anchor biosynthesis, dihydroorotate dehydrogenase-mediated pyrimidine synthesis, chitin synthase, and fungal mitochondrial respiration. In addition, drugs with novel delivery systems, such as opelconazole, thin film freezing-voriconazole, encochleated amphotericin B (CAmB), and turletricin, aim to preserve broad-spectrum fungicidal activity while minimizing systemic toxicity. Beyond small molecules, antifungal vaccines, immunotherapies, and T cell-based approaches are emerging as promising adjuncts to conventional treatments. A multidisciplinary approach to expanding the antifungal armamentarium with novel therapeutics is critical to address the urgent and growing burden of invasive fungal disease.